{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T07:50:09Z","timestamp":1773215409920,"version":"3.50.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T00:00:00Z","timestamp":1733097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003243","name":"Ministerstvo Zdravotnictv\u00ed Cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["MMCI 00209805"],"award-info":[{"award-number":["MMCI 00209805"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001824","name":"Grantov\u00e1 Agentura \u010cesk\u00e9 Republiky","doi-asserted-by":"publisher","award":["GACR 23-05951S"],"award-info":[{"award-number":["GACR 23-05951S"]}],"id":[{"id":"10.13039\/501100001824","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>TP73<\/jats:italic> is a member of the <jats:italic>TP53<\/jats:italic> gene family and produces N- and C-terminal protein isoforms through alternative promoters, alternative translation initiation and alternative splicing. Most notably, p73 protein isoforms may either contain a p53-like transactivation domain (TAp73 isoforms) or lack this domain (\u0394TAp73 isoforms) and these variants have opposing or independent functions. To date, there is a lack of well-characterised isoform-specific p73 antibodies. Here, we produced polyclonal and monoclonal antibodies to N-terminal p73 variants and the C-terminal p73\u03b1 isoform, the most common variant in human tissues. These reagents show that TAp73 is a marker of multiciliated epithelial cells, while \u0394TAp73 is a marker of non-proliferative basal\/reserve cells in squamous epithelium. We were unable to detect \u0394Np73 variant proteins, in keeping with recent data that this is a minor form in human tissues. Most cervical squamous cell carcinomas (79%) express p73\u03b1, and the distribution of staining in basal cells correlated with lower tumour grade. TAp73 was found in 17% of these tumours, with a random distribution and no association with clinicopathological features. These data indicate roles for \u0394TAp73 in maintaining a non-proliferative state of undifferentiated squamous epithelial cells and for TAp73 in the production of differentiated multiciliated cells.<\/jats:p>","DOI":"10.1038\/s41598-024-80927-9","type":"journal-article","created":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T14:21:25Z","timestamp":1733149285000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["TAp73 and \u0394TAp73 isoforms show cell-type specific distributions and alterations in cancer"],"prefix":"10.1038","volume":"14","author":[{"given":"Vaclav","family":"Hrabal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michaela","family":"Stenckova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filip","family":"Zavadil Kokas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petr","family":"Muller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rudolf","family":"Nenutil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Borivoj","family":"Vojtesek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip J.","family":"Coates","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,12,2]]},"reference":[{"key":"80927_CR1","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/278261a0","volume":"278","author":"DP Lane","year":"1979","unstructured":"Lane, D. P. & Crawford, L. V. T antigen is bound to a host protein in SV40-transformed cells. Nature 278, 261\u2013263 (1979).","journal-title":"Nature"},{"key":"80927_CR2","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/0042-6822(79)90554-3","volume":"98","author":"DI Linzer","year":"1979","unstructured":"Linzer, D. I., Maltzman, W. & Levine, A. J. The SV40 A gene product is required for the production of a 54,000\u00a0MW cellular tumor antigen. Virology 98, 308\u2013318 (1979).","journal-title":"Virology"},{"key":"80927_CR3","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1038\/sj.onc.1201500","volume":"15","author":"H Schmale","year":"1997","unstructured":"Schmale, H. & Bamberger, C. A novel protein with strong homology to the tumor suppressor p53. Oncogene 15, 1363\u20131367 (1997).","journal-title":"Oncogene"},{"key":"80927_CR4","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/S0092-8674(00)80540-1","volume":"90","author":"M Kaghad","year":"1997","unstructured":"Kaghad, M. et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90, 809\u2013819 (1997).","journal-title":"Cell"},{"key":"80927_CR5","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1016\/j.ccell.2024.04.009","volume":"42","author":"Y Liu","year":"2024","unstructured":"Liu, Y., Su, Z., Tavana, O. & Gu, W. Understanding the complexity of p53 in a new era of tumor suppression. Cancer Cell. 42, 946\u2013967 (2024).","journal-title":"Cancer Cell."},{"key":"80927_CR6","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1126\/science.277.5332.1605","volume":"277","author":"S Dickman","year":"1997","unstructured":"Dickman, S. First p53 relative may be a new tumor suppressor. Science 277, 1605\u20131606 (1997).","journal-title":"Science"},{"key":"80927_CR7","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1038\/38298","volume":"389","author":"CA Jost","year":"1997","unstructured":"Jost, C. A., Marin, M. C. & Kaelin, W. G. p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature 389, 191\u2013194 (1997).","journal-title":"Nature"},{"key":"80927_CR8","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/19539","volume":"398","author":"A Yang","year":"1999","unstructured":"Yang, A. et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature 398, 714\u2013718 (1999).","journal-title":"Nature"},{"key":"80927_CR9","doi-asserted-by":"publisher","first-page":"jcs233338","DOI":"10.1242\/jcs.233338","volume":"132","author":"A Nemajerova","year":"2019","unstructured":"Nemajerova, A. & Moll, U. M. Tissue-specific roles of p73 in development and homeostasis. J. Cell. Sci. 132, jcs233338 (2019).","journal-title":"J. Cell. Sci."},{"key":"80927_CR10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1007\/978-94-017-9211-0_2","volume":"85","author":"K Inoue","year":"2014","unstructured":"Inoue, K. & Fry, E. A. Alterations of p63 and p73 in human cancers. Subcell. Biochem. 85, 17\u201340 (2014).","journal-title":"Subcell. Biochem."},{"key":"80927_CR11","first-page":"503","volume":"30","author":"P Orzol","year":"2015","unstructured":"Orzol, P. et al. The diverse oncogenic and tumour suppressor roles of p63 and p73 in cancer: a review by cancer site. Histol. Histopathol. 30, 503\u2013521 (2015).","journal-title":"Histol. Histopathol"},{"key":"80927_CR12","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1002\/path.5656","volume":"254","author":"Z Pokorn\u00e1","year":"2021","unstructured":"Pokorn\u00e1, Z., Vyslou\u017eil, J., Hrabal, V., Vojt\u011b\u0161ek, B. & Coates, P. J. The foggy world(s) of p63 isoform regulation in normal cells and cancer. J. Pathol. 254, 454\u2013473 (2021).","journal-title":"J. Pathol."},{"key":"80927_CR13","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1016\/j.jmb.2018.04.034","volume":"430","author":"P Vikhreva","year":"2018","unstructured":"Vikhreva, P., Melino, G. & Amelio, I. p73 alternative splicing: exploring a Biological role for the C-Terminal isoforms. J. Mol. Biol. 430, 1829\u20131838 (2018).","journal-title":"J. Mol. Biol."},{"key":"80927_CR14","doi-asserted-by":"crossref","unstructured":"L\u00f3pez, I., Valdivia, I. L., Vojtesek, B., F\u00e5hraeus, R. & Coates, P. J. Re-appraising the evidence for the source, regulation and function of p53-family isoforms. Nucleic Acids Res. 52, 12112\u201312129 (2024).","DOI":"10.1093\/nar\/gkae855"},{"key":"80927_CR15","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1038\/sj.cdd.4400962","volume":"8","author":"TJ Grob","year":"2001","unstructured":"Grob, T. J. et al. Human delta Np73 regulates a dominant negative feedback loop for TAp73 and p53. Cell. Death Differ. 8, 1213\u20131223 (2001).","journal-title":"Cell. Death Differ."},{"key":"80927_CR16","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1089\/bio.2015.29031.hmm","volume":"13","author":"LJ Carithers","year":"2015","unstructured":"Carithers, L. J. & Moore, H. M. The genotype-tissue expression (GTEx) project. Biopreservation Biobanking. 13, 307\u2013308 (2015).","journal-title":"Biopreservation Biobanking"},{"key":"80927_CR17","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/nature24277","volume":"550","author":"GTEx","year":"2017","unstructured":"GTEx et al. Genetic effects on gene expression across human tissues. Nature 550, 204\u2013213 (2017).","journal-title":"Nature"},{"key":"80927_CR18","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/s41419-021-04017-8","volume":"12","author":"CB Marshall","year":"2021","unstructured":"Marshall, C. B. et al. Tissue-specific expression of p73 and p63 isoforms in human tissues. Cell. Death Dis. 12, 745 (2021).","journal-title":"Cell. Death Dis."},{"key":"80927_CR19","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/35003607","volume":"404","author":"A Yang","year":"2000","unstructured":"Yang, A. et al. p73-deficient mice have neurological, pheromonal and inflammatory defects but lack spontaneous tumours. Nature 404, 99\u2013103 (2000).","journal-title":"Nature"},{"key":"80927_CR20","doi-asserted-by":"publisher","first-page":"716957","DOI":"10.3389\/fcell.2021.716957","volume":"9","author":"L Maeso-Alonso","year":"2021","unstructured":"Maeso-Alonso, L., L\u00f3pez-Ferreras, L. & Marques, M. M. Marin, M. C. p73 as a tissue architect. Front. Cell. Dev. Biol. 9, 716957 (2021).","journal-title":"Front. Cell. Dev. Biol."},{"key":"80927_CR21","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1016\/j.celrep.2016.02.035","volume":"14","author":"CB Marshall","year":"2016","unstructured":"Marshall, C. B. et al. p73 is required for Multiciliogenesis and regulates the Foxj1-Associated Gene Network. Cell. Rep. 14, 2289\u20132300 (2016).","journal-title":"Cell. Rep."},{"key":"80927_CR22","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1101\/gad.283663.116","volume":"30","author":"M Napoli","year":"2016","unstructured":"Napoli, M. & Flores, E. R. Unifying the p73 knockout phenotypes: TAp73 orchestrates multiciliogenesis. Genes Dev. 30, 1253\u20131254 (2016).","journal-title":"Genes Dev."},{"key":"80927_CR23","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1038\/cdd.2017.178","volume":"25","author":"A Nemajerova","year":"2018","unstructured":"Nemajerova, A. et al. Non-oncogenic roles of TAp73: from multiciliogenesis to metabolism. Cell. Death Differ. 25, 144\u2013153 (2018).","journal-title":"Cell. Death Differ."},{"key":"80927_CR24","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/01.pgp.0000092133.88121.98","volume":"22","author":"R Nenutil","year":"2003","unstructured":"Nenutil, R., Ceskova, P., Coates, P. J., Nylander, K. & Vojtesek, B. Differential expression of p73alpha in normal ectocervical epithelium, cervical intraepithelial neoplasia, and invasive squamous cell carcinoma. Int. J. Gynecol. Pathol. Off J. Int. Soc. Gynecol. Pathol. 22, 386\u2013392 (2003).","journal-title":"Int. J. Gynecol. Pathol. Off J. Int. Soc. Gynecol. Pathol."},{"key":"80927_CR25","first-page":"5642","volume":"9","author":"P Puig","year":"2003","unstructured":"Puig, P. et al. p73 expression in human normal and tumor tissues: loss of p73alpha expression is associated with tumor progression in bladder cancer. Clin. Cancer Res. Off J. Am. Assoc. Cancer Res. 9, 5642\u20135651 (2003).","journal-title":"Clin. Cancer Res. Off J. Am. Assoc. Cancer Res."},{"key":"80927_CR26","doi-asserted-by":"publisher","first-page":"3702","DOI":"10.4161\/cc.8.22.10036","volume":"8","author":"JM Rosenbluth","year":"2009","unstructured":"Rosenbluth, J. M., Johnson, K., Tang, L., Triplett, T. & Pietenpol, J. A. Evaluation of p63 and p73 antibodies for cross-reactivity. Cell. Cycle Georget. Tex. 8, 3702\u20133706 (2009).","journal-title":"Cell. Cycle Georget. Tex."},{"key":"80927_CR27","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1007\/s00428-013-1459-4","volume":"463","author":"M Nekulova","year":"2013","unstructured":"Nekulova, M. et al. Characterization of specific p63 and p63-N-terminal isoform antibodies and their application for immunohistochemistry. Virchows Arch. Int. J. Pathol. 463, 415\u2013425 (2013).","journal-title":"Virchows Arch. Int. J. Pathol."},{"key":"80927_CR28","doi-asserted-by":"publisher","first-page":"3156","DOI":"10.1073\/pnas.061032098","volume":"98","author":"G Pellegrini","year":"2001","unstructured":"Pellegrini, G. et al. p63 identifies keratinocyte stem cells. Proc. Natl. Acad. Sci. U S A. 98, 3156\u20133161 (2001).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"80927_CR29","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41419-024-06783-7","volume":"15","author":"Y Guo","year":"2024","unstructured":"Guo, Y., Wu, H., Wiesm\u00fcller, L. & Chen, M. Canonical and non-canonical functions of p53 isoforms: potentiating the complexity of tumor development and therapy resistance. Cell. Death Dis. 15, 412 (2024).","journal-title":"Cell. Death Dis."},{"key":"80927_CR30","doi-asserted-by":"publisher","first-page":"737735","DOI":"10.3389\/fcell.2021.737735","volume":"9","author":"S Logotheti","year":"2021","unstructured":"Logotheti, S. et al. Mechanisms of functional pleiotropy of p73 in Cancer and Beyond. Front. Cell. Dev. Biol. 9, 737735 (2021).","journal-title":"Front. Cell. Dev. Biol."},{"key":"80927_CR31","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1158\/0008-5472.CAN-03-1060","volume":"64","author":"N Concin","year":"2004","unstructured":"Concin, N. et al. Transdominant DeltaTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res. 64, 2449\u20132460 (2004).","journal-title":"Cancer Res."},{"key":"80927_CR32","doi-asserted-by":"publisher","first-page":"a004887","DOI":"10.1101\/cshperspect.a004887","volume":"2","author":"V D\u00f6tsch","year":"2010","unstructured":"D\u00f6tsch, V., Bernassola, F., Coutandin, D., Candi, E. & Melino, G. p63 and p73, the ancestors of p53. Cold Spring Harb Perspect. Biol. 2, a004887 (2010).","journal-title":"Cold Spring Harb Perspect. Biol."},{"key":"80927_CR33","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1038\/d41586-020-02549-1","volume":"585","author":"M Baker","year":"2020","unstructured":"Baker, M. When antibodies mislead: the quest for validation. Nature 585, 313\u2013314 (2020).","journal-title":"Nature"},{"key":"80927_CR34","doi-asserted-by":"publisher","first-page":"e100211","DOI":"10.7554\/eLife.100211","volume":"13","author":"RA Kahn","year":"2024","unstructured":"Kahn, R. A. et al. Antibody characterization is critical to enhance reproducibility in biomedical research. eLife 13, e100211 (2024).","journal-title":"eLife"},{"key":"80927_CR35","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.3389\/fphys.2019.01551","volume":"10","author":"TD Pham","year":"2019","unstructured":"Pham, T. D., Fan, C., Pfeifer, D., Zhang, H. & Sun, X. F. Image-based network analysis of DNp73 expression by immunohistochemistry in rectal Cancer patients. Front. Physiol. 10, 1551 (2019).","journal-title":"Front. Physiol."},{"key":"80927_CR36","doi-asserted-by":"publisher","first-page":"5861","DOI":"10.1038\/onc.2010.319","volume":"29","author":"AE Vilgelm","year":"2010","unstructured":"Vilgelm, A. E. et al. Characterization of \u2206Np73 expression and regulation in gastric and esophageal tumors. Oncogene 29, 5861\u20135868 (2010).","journal-title":"Oncogene"},{"key":"80927_CR37","doi-asserted-by":"publisher","first-page":"e0218458","DOI":"10.1371\/journal.pone.0218458","volume":"14","author":"JS Beeler","year":"2019","unstructured":"Beeler, J. S. et al. p73 regulates epidermal wound healing and induced keratinocyte programming. PloS One. 14, e0218458 (2019).","journal-title":"PloS One"},{"key":"80927_CR38","doi-asserted-by":"publisher","first-page":"154","DOI":"10.3389\/fgene.2019.00154","volume":"10","author":"MM Marques","year":"2019","unstructured":"Marques, M. M., Villoch-Fernandez, J., Maeso-Alonso, L., Fuertes-Alvarez, S. & Marin, M. C. The Trp73 mutant mice: a Ciliopathy Model that uncouples Ciliogenesis from Planar Cell Polarity. Front. Genet. 10, 154 (2019).","journal-title":"Front. Genet."},{"key":"80927_CR39","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/path.5511","volume":"252","author":"DR Cochrane","year":"2020","unstructured":"Cochrane, D. R. et al. Single cell transcriptomes of normal endometrial derived organoids uncover novel cell type markers and cryptic differentiation of primary tumours. J. Pathol. 252, 201\u2013214 (2020).","journal-title":"J. Pathol."},{"key":"80927_CR40","first-page":"636","volume":"62","author":"O Ishimoto","year":"2002","unstructured":"Ishimoto, O. et al. Possible oncogenic potential of DeltaNp73: a newly identified isoform of human p73. Cancer Res. 62, 636\u2013641 (2002).","journal-title":"Cancer Res."},{"key":"80927_CR41","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1084\/jem.20020179","volume":"196","author":"AI Zaika","year":"2002","unstructured":"Zaika, A. I. et al. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J. Exp. Med. 196, 765\u2013780 (2002).","journal-title":"J. Exp. Med."},{"key":"80927_CR42","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.4161\/cc.24967","volume":"12","author":"C Di","year":"2013","unstructured":"Di, C. et al. Mechanisms, function and clinical applications of DNp73. Cell. Cycle Georget. Tex. 12, 1861\u20131867 (2013).","journal-title":"Cell. Cycle Georget. Tex."},{"key":"80927_CR43","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1196\/annals.1397.035","volume":"1095","author":"AE Sayan","year":"2007","unstructured":"Sayan, A. E. et al. Generation of DeltaTAp73 proteins by translation from a putative internal ribosome entry site. Ann. N Y Acad. Sci. 1095, 315\u2013324 (2007).","journal-title":"Ann. N Y Acad. Sci."},{"key":"80927_CR44","doi-asserted-by":"publisher","first-page":"3371","DOI":"10.1038\/s41388-023-02859-4","volume":"42","author":"Y Li","year":"2023","unstructured":"Li, Y. et al. p63: a crucial player in epithelial stemness regulation. Oncogene 42, 3371\u20133384 (2023).","journal-title":"Oncogene"},{"key":"80927_CR45","first-page":"772","volume":"139","author":"RA Romano","year":"2012","unstructured":"Romano, R. A. et al. \u2206Np63 knockout mice reveal its indispensable role as a master regulator of epithelial development and differentiation. Dev. Camb. Engl. 139, 772\u2013782 (2012).","journal-title":"Dev. Camb. Engl."},{"key":"80927_CR46","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/s41419-023-06213-0","volume":"14","author":"A Strubel","year":"2023","unstructured":"Strubel, A. et al. DARPins detect the formation of hetero-tetramers of p63 and p73 in epithelial tissues and in squamous cell carcinoma. Cell. Death Dis. 14, 674 (2023).","journal-title":"Cell. Death Dis."},{"key":"80927_CR47","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s00428-018-2324-2","volume":"472","author":"PJ Coates","year":"2018","unstructured":"Coates, P. J. et al. p63 isoforms in triple-negative breast cancer: \u2206Np63 associates with the basal phenotype whereas TAp63 associates with androgen receptor, lack of BRCA mutation, PTEN and improved survival. Virchows Arch. Int. J. Pathol. 472, 351\u2013359 (2018).","journal-title":"Virchows Arch. Int. J. Pathol."},{"key":"80927_CR48","first-page":"14","volume":"43","author":"L Loljung","year":"2014","unstructured":"Loljung, L. et al. High expression of p63 is correlated to poor prognosis in squamous cell carcinoma of the tongue. J. Oral Pathol. Med. Off Publ Int. Assoc. Oral Pathol. Am. Acad. Oral Pathol. 43, 14\u201319 (2014).","journal-title":"J. Oral Pathol. Med. Off Publ Int. Assoc. Oral Pathol. Am. Acad. Oral Pathol."},{"key":"80927_CR49","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/nmeth947","volume":"3","author":"O S\u00f6derberg","year":"2006","unstructured":"S\u00f6derberg, O. et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat. Methods. 3, 995\u20131000 (2006).","journal-title":"Nat. Methods"},{"key":"80927_CR50","first-page":"309","volume":"13","author":"SG Silverberg","year":"2000","unstructured":"Silverberg, S. G. Problems in the differential diagnosis of endometrial hyperplasia and carcinoma. Mod. Pathol. Off J. U S Can. Acad. Pathol. Inc. 13, 309\u2013327 (2000).","journal-title":"Mod. Pathol. Off J. U S Can. Acad. Pathol. Inc"},{"key":"80927_CR51","doi-asserted-by":"publisher","first-page":"4009","DOI":"10.3390\/cells11244009","volume":"11","author":"MT Richardson","year":"2022","unstructured":"Richardson, M. T., Recouvreux, M. S., Karlan, B. Y., Walts, A. E. & Orsulic, S. Ciliated cells in Ovarian Cancer decrease with increasing Tumor Grade and Disease Progression. Cells 11, 4009 (2022).","journal-title":"Cells"},{"key":"80927_CR52","doi-asserted-by":"publisher","first-page":"5462","DOI":"10.1073\/pnas.97.10.5462","volume":"97","author":"K Hibi","year":"2000","unstructured":"Hibi, K. et al. AIS is an oncogene amplified in squamous cell carcinoma. Proc. Natl. Acad. Sci. U S A. 97, 5462\u20135467 (2000).","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"80927_CR53","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1002\/path.1231","volume":"198","author":"K Nylander","year":"2002","unstructured":"Nylander, K. et al. Differential expression of p63 isoforms in normal tissues and neoplastic cells. J. Pathol. 198, 417\u2013427 (2002).","journal-title":"J. Pathol."},{"key":"80927_CR54","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1093\/bioinformatics\/btv522","volume":"32","author":"A Krejci","year":"2016","unstructured":"Krejci, A., Hupp, T. R., Lexa, M., Vojtesek, B. & Muller, P. Hammock: a hidden Markov model-based peptide clustering algorithm to identify protein-interaction consensus motifs in large datasets. Bioinforma Oxf. Engl. 32, 9\u201316 (2016).","journal-title":"Bioinforma Oxf. Engl."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80927-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80927-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80927-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,2]],"date-time":"2024-12-02T15:06:00Z","timestamp":1733151960000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-80927-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,2]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["80927"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-80927-9","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,2]]},"assertion":[{"value":"12 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"BV is a consultant for Moravian-Biotechnology spol. s r.o., who produced the antibodies used in this study. The company did not provide financial support for the study and had no influence on the design, execution or reporting of the work. All other authors report no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29949"}}